Kite Pharma’s Yescarta Approved for Adult Lymphoma Treatment
March 29, 2021, 10:06 am
Santa Monica-based Kite Pharma announced March 5 that the Food and Drug Administration has granted accelerated approval for the company’s principal drug, Yescarta, for the treatment of adult patients with relapsed follicular lymphoma after two or more other therapies had already been applied.
